ArticleMedical science monitor : international medical journal of experimental and clinical research2017
Gypenosides Inhibits Xanthine Oxidoreductase and Ameliorates Urate Excretion in Hyperuricemic Rats Induced by High Cholesterol and High Fat Food (Lipid Emulsion).
Article in Medical science monitor : international medical journal of experimental and clinical research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 65 citations in OpenAlex.
- Saponins Derived from Chinese Medicinal Materials in Hyperuricemia and Gout: Therapeutic Mechanisms and Emerging Perspectives.Molecules (Basel, Switzerland) · 2026Review
- Phytotherapeutic insights into hyperuricemia: a mechanistic and clinical perspective.Inflammopharmacology · 2025Review
- The anti-hyperuricemia potential of bioactive natural products and extracts derived from traditional Chinese medicines: A review and perspective.Journal of pharmaceutical analysis · 2025Review
- Therapeutic potential and pharmacological mechanisms of Traditional Chinese Medicine in gout treatment.Acta pharmacologica Sinica · 2025Review
- Gypenosides, a promising phytochemical triterpenoid: research progress on its pharmacological activity and mechanism.Frontiers in pharmacology · 2025Review
- Advances in Traditional Chinese Medicine for the treatment of hyperuricemia and associated diseases: pathogenesis, mechanisms, and future directions.Frontiers in nutrition · 2025Review
- Bacoside a inhibits the growth of glioma by promoting apoptosis and autophagy in U251 and U87 cells.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Article
- Hyperuricemia research progress in model construction and traditional Chinese medicine interventions.Frontiers in pharmacology · 2024Review
- Saponins of Tomato Extract Improve Non-Alcoholic Fatty Liver Disease by Regulating Oxidative Stress and Lipid Homeostasis.Antioxidants (Basel, Switzerland) · 2023Article
- Article
- Therapeutic effects and mechanisms of N-(9,10-anthraquinone-2-ylcarbonyl) xanthine oxidase inhibitors on hyperuricemia.Frontiers in pharmacology · 2022Article
- Progress in the Medicinal Value, Bioactive Compounds, and Pharmacological Activities ofMolecules (Basel, Switzerland) · 2021Review
- Advances in Experimental and Clinical Research of the Gouty Arthritis Treatment with Traditional Chinese Medicine.Evidence-based complementary and alternative medicine : eCAM · 2021Review
- Drug Transporters in the Kidney: Perspectives on Species Differences, Disease Status, and Molecular Docking.Frontiers in pharmacology · 2021Review
- Potential Application of Plant-Based Functional Foods in the Development of Immune Boosters.Frontiers in pharmacology · 2021Review
- Anti-Hyperuricemic and Nephroprotective Effects of Dihydroberberine in Potassium Oxonate- and Hypoxanthine-Induced Hyperuricemic Mice.Frontiers in pharmacology · 2021Article
- Exercise or Dietotherapy Is Not Better than Returning to a Regular Diet to Rebuild Lipid Homeostasis of Rats.BioMed research international · 2021Article
- Anti-Hyperuricemic Effects of Astaxanthin by Regulating Xanthine Oxidase, Adenosine Deaminase and Urate Transporters in Rats.Marine drugs · 2020Article
- Lifeceramics-treated water reduces serum uric acid levels and improves hemorheological activity in hyperuricemic rats.Biomedical reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND The aim of this study was to study the effects of gypenosides (GPS) on lowering uric acid (UA) levels in hyperuricemic rats induced by lipid emulsion (LE) and the related mechanisms. GPS are natural saponins extracted from Gynostemma pentaphyllum. MATERIAL AND METHODS Forty-eight male SD rats were randomly divided into six groups: normal, model, two positive controls, and two GPS treated groups (two different doses of GPS). The normal group rats were fed a basic diet, and the other rats were orally pretreated with LE. Urine and blood were collected at regular intervals. Full automatic biochemical analyzer was used to detect the concentration levels of serum UA (SUA), serum creatinine (SCr), BUN, and urine UA (UUA), and urine creatinine (UCr) and fractional excretion of UA (FEUA). ELISA kits were used to detect enzymes activities: xanthine oxidase (XOD), adenosime deaminase (ADA), guanine deaminase (GDA), and xanthine dehydrogenase (XDH). Immunohistochemistry was used to observe kidney changes and protein (URAT1, GLUT9, and OAT1) expression levels. RT-PCR was used to detect the relevant mRNA expression levels. RESULTS Treatment with GPS significantly reduced the SUA, prevented abnormal weight loss caused by LE, and improved kidney pathomorphology. Treatment with GPS also decreased the levels of XOD, ADA, and XDH expression, increased the kidney index and FEUA, downregulated URAT1 and GLUT9 expression and upregulated OAT1 expression in the kidney. CONCLUSIONS GPS may be an effective treatment for hyperuricemia via a decrease in xanthine oxidoreductase through the XOD/XDH system; and via an increase in urate excretion through regulating URAT1, GLUT9, and OAT1 transporters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.